Acute pancreatitis without abdominal pain induced by administration of nivolumab and ipilimumab.

Published on Apr 6, 2021
· DOI :10.1080/24725625.2021.1899444
Koichiro Yamamoto2
Estimated H-index: 2
(Okayama University),
Kosuke Oka2
Estimated H-index: 2
(Okayama University)
+ 7 AuthorsFumio Otsuka35
Estimated H-index: 35
(Okayama University)
Immune checkpoint inhibitors (ICIs) such as nivolumab and ipilimumab are emerging agents for the treatment of cancers including melanoma. ICIs are known to cause immune-related adverse events (irAEs), including the development of enterocolitis, dermatitis, and nephritis. However, ICI-induced pancreatitis has seldom been reported, and its pathophysiology and clinical importance remain largely unknown. We describe a 76-year-old man with melanoma who developed acute pancreatitis without abdominal pain after immunotherapy with nivolumab and ipilimumab. The patient was referred due to 2-week-long general fatigue, anorexia, and dermatitis after his second immunotherapy. Laboratory examinations in serum showed high inflammation and renal dysfunction. Plain computed tomography (CT) on admission showed no new lesions including colitis or pancreatitis. On the 4th day of hospitalisation, serum pancreatic enzymes were extremely elevated. Amylase was increased to 683 U/L (normal range: 44-132) and lipase was increased to 1520 U/L (13-55), but he had no abdominal tenderness. Contrast-enhanced CT showed enlarged pancreatic parenchyma and magnetic resonance cholangiopancreatography showed peripancreatic fat stranding, suggesting pancreatitis. Blood culture tests and empirical antibiotic therapy with ceftriaxone indicated no active infectious diseases. We diagnosed ICI-induced pancreatitis and treated him with 0.5 mg/kg/day of prednisolone, which improved his general fatigue, anorexia, dermatitis, and pancreatitis. The potential significance of asymptomatic elevations of pancreatic enzymes has been unclear; however, this case suggested that ICI-induced pancreatitis without abdominal tenderness could be clinically significant. Clinicians should pay attention to the development of latent pancreatitis in patients receiving ICIs, even those without abdominal pain.
📖 Papers frequently viewed together
6 Authors (Chinatsu Kasahara, ..., Hiroshi Ito)
1 Citations
6 Authors (Helena Clayton, ..., Curdin Conrad)
8 Citations
#1Manuel Ramos-Casals (University of Barcelona)H-Index: 90
#2Julie R. Brahmer (Johns Hopkins University)H-Index: 90
Last. Maria E. Suarez-Almazor (University of Texas MD Anderson Cancer Center)H-Index: 77
view all 10 authors...
Cancer immunotherapies have changed the landscape of cancer treatment during the past few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and CTLA-4, are increasingly used for certain cancers; however, this increased use has resulted in increased reports of immune-related adverse events (irAEs). These irAEs are unique and are different to those of traditional cancer therapies, and typically have a delayed onset and prolonged duration. IrAEs can involve any organ or sy...
18 CitationsSource
3 CitationsSource
#1Takeshi Tanaka (Kobe University)H-Index: 4
#2Arata Sakai (Kobe University)H-Index: 7
Last. Yuzo Kodama (Kobe University)H-Index: 35
view all 6 authors...
3 CitationsSource
#1John George (Bridgeport Hospital)H-Index: 7
#2Divyansh Bajaj (Quinnipiac University)H-Index: 4
Last. James J. Farrell (Yale University)H-Index: 20
view all 8 authors...
Abstract Background Systemic immune side effects including pancreatitis have been reported with the use of Immune Checkpoint Inhibitors (ICI) (CTLA-4, PD-1 and PDL-1). However, the true incidence, risk, causes (tumor or drug specific) of pancreatitis and relation to other immune side effects, especially diabetes mellitus (DM) are unknown. Methods We performed a systematic review and meta-analysis of all clinical trials using ICI for the incidence of any grade lipase elevation, pancreatitis or DM...
14 CitationsSource
#1John A. Thompson (Seattle Cancer Care Alliance)H-Index: 33
#2Bryan J. Schneider (UM: University of Michigan)H-Index: 24
Last. Jillian L. Scavone (National Comprehensive Cancer Network)H-Index: 9
view all 31 authors...
: The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenter...
162 CitationsSource
#1Cheng Xu (SYSU: Sun Yat-sen University)H-Index: 11
#2Yu Pei Chen (SYSU: Sun Yat-sen University)H-Index: 18
Last. Jun Ma (SYSU: Sun Yat-sen University)H-Index: 18
view all 15 authors...
Abstract Objective To provide a complete toxicity profile, toxicity spectrum, and a safety ranking of immune checkpoint inhibitor (ICI) drugs for treatment of cancer. Design Systematic review and network meta-analysis. Data sources Electronic databases (PubMed, Embase, Cochrane Library, and Web of Science) were systematically searched to include relevant studies published in English between January 2007 and February 2018. Review methods Only head-to-head phase II and III randomised controlled tr...
106 CitationsSource
#1Rong Jiang (Nanjing Medical University)H-Index: 1
#2Li XuH-Index: 1
Last. Ziyan DuH-Index: 1
view all 8 authors...
5 CitationsSource
#1Qiang Su (Capital Medical University)H-Index: 6
#2Xiao-chen Zhang (THU: Tsinghua University)H-Index: 3
Last. Bangwei Cao (Capital Medical University)H-Index: 12
view all 6 authors...
We performed a systematic review and meta-analysis to determine the risk of immune-related pancreatitis associated with the treatment by immune checkpoint inhibitors (ICIs) for solid tumors. Eligible studies were selected from multiple databases including phase II/III randomized controlled trials (RCTs) with ICIs in solid tumor patients. The data were analyzed with Stata version 12.0 software. After excluding ineligible studies, a total of 15 clinical trials were considered eligible for the meta...
19 CitationsSource
The development of immune checkpoint inhibitors [monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1)] represents a major breakthrough in cancer therapy. Although they present a favorable risk/benefit ratio, immune checkpoint blockade therapies have a very specific safety profile. Due to their unique mechanism of action, they entail a new spectrum of adverse events that are mostly immune ...
157 CitationsSource
#1Daisuke Nango (Meiji Pharmaceutical University)H-Index: 2
#2Hiroki NakashimaH-Index: 1
Last. Hirotoshi Echizen (Meiji Pharmaceutical University)H-Index: 25
view all 5 authors...
Background A causal relationship between acute pancreatitis and administration of glucocorticoids remains a matter of debate, since most of the reported cases were diagnosed with systemic vascular diseases (including systemic lupus erythematosus and polyarteritis nodosa) that may be responsible for the pancreatitis.
5 CitationsSource
Cited By0